Meet
Ekemini Isaiah

Ekemini advises a broad array of healthcare clients on the impact of federal and state health policy developments on their business priorities and policy engagement strategies.

Her background in federal health reform, comparative health systems, and the social determinants of health are critical as she works with clients on topics including drug pricing, physician payment, Medicare reimbursement, patient access, and other healthcare reforms.

Prior to joining Avalere, Ekemini worked as an associate at Sachs Policy Group, a health policy consulting firm in New York City, where she supported clients with state and federal regulatory analyses and oversaw grant projects for clients that arose from the New York State Delivery System Reform Incentive Payment program. Ekemini also worked as a visiting research scholar at the London School of Economics in the Personal Social Services Research Unit analyzing long-term care systems, interventions, and policy measures to reduce dependency cost effectively across the European Union.

Ekemini earned an MPH in health policy and management from New York University and a BS from Cornell University in biology and society.

Authored Content


CMMI’s impact on Medicare spending has not reached earlier projections by the Congressional Budget Office (CBO), demonstrating the difficulty in projecting savings from untested and future unknown alternative payment models

Avalere analysis finds that tying Medicare Part D manufacturer discounts to utilization in the catastrophic phase instead of in the coverage gap would have differential impacts by disease area.

Avalere analysis finds that 24 of the top 50 non-vaccine Part B drugs are not on the U.S. Department of Veterans Affairs’ National Formulary.

As policymakers explore opportunities to reform Medicare Part B, a tiered average sales price (ASP) add-on payment may be under consideration to align system incentives and curb spending.

New Avalere analysis finds that most seniors in Medicare would not see a reduction in their out-of-pocket costs as a result of the International Price Index Model.